FluMist May Require Additional Phase III Trial To Expand Patient Population
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.
You may also be interested in...
MedImmune’s Refrigerated FluMist To Be Priced At Slight Discount To Old Formulation
The firm will focus marketing efforts on pediatricians.
MedImmune’s Refrigerated FluMist To Be Priced At Slight Discount To Old Formulation
The firm will focus marketing efforts on pediatricians.
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.